0000899243-22-020410.txt : 20220601
0000899243-22-020410.hdr.sgml : 20220601
20220601162747
ACCESSION NUMBER: 0000899243-22-020410
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220527
FILED AS OF DATE: 20220601
DATE AS OF CHANGE: 20220601
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Strobeck Matthew
CENTRAL INDEX KEY: 0001377832
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-10961
FILM NUMBER: 22987717
MAIL ADDRESS:
STREET 1: C/O METABOLIX, INC.
STREET 2: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: QUIDEL CORP /DE/
CENTRAL INDEX KEY: 0000353569
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 942573850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9975 SUMMERS RIDGE ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8585521100
MAIL ADDRESS:
STREET 1: 9975 SUMMERS RIDGE ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/
DATE OF NAME CHANGE: 19910210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-27
1
0000353569
QUIDEL CORP /DE/
QDEL
0001377832
Strobeck Matthew
9975 SUMMERS RIDGE ROAD
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2022-05-27
4
D
0
6533
D
0
D
Common Stock
2022-05-27
4
D
0
16630
D
0
I
UGMA Account
Common Stock
2022-05-27
4
D
0
38145
D
0
I
Birchview
Non-Qualified Stock Options
53.27
2022-05-27
4
D
0
259
0.00
D
2028-04-04
Common Stock
259
0
D
Restricted Stock Units
2022-05-27
4
D
0
875
0.00
D
Common Stock
875
0
D
Restricted Stock Units
2022-05-27
4
D
0
262
0.00
D
Common Stock
262
0
D
Restricted Stock Units
2022-05-27
4
D
0
427
0.00
D
Common Stock
427
0
D
Restricted Stock Units
2022-05-27
4
D
0
85
0.00
D
Common Stock
85
0
D
Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
The Reporting Person is custodian under the Uniform Gift to Minor Act of 16,630 shares held by four of the Reporting Person's children. The Reporting Person disclaims beneficial ownership of these shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The Reporting Person has sole voting and dispositive power with respect to shares held by Birchview Fund, LLC in his capacity as the Chief Executive Officer of such entity. The Reporting Person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
Vested in full.
Each restricted stock unit represents the right to receive one share of Quidel common stock.
Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
/s/ Phillip S. Askim, attorney-in-fact for Matthew Strobeck
2022-06-01